World Health Organization

WHO Town Hall for civil society and affected communities on ending TB

On 9 June 2022, the World Health Organization (WHO) will convene a civil society Town Hall on ending TB in close collaboration with the WHO Civil Society Task Force on TB. The Town Hall will be led by WHO Director-General, senior WHO leadership and members of the Task Force.

Read More →

WHO issues Information Note on ensuring continuity of essential TB services for people with or at risk of the disease in Ukraine and refugee-hosting countries

19 May 2022 | Geneva: The World Health Organization (WHO) is working closely with Ukraine, countries hosting refugees, affected populations and partners to rapidly respond to the humanitarian crisis caused by war and minimize disruptions to the delivery of critical health care services. As part of these overarching efforts, WHO is working to enable access to tuberculosis (TB) care services for all people with or at risk of TB within Ukraine and in refugee-hosting countries.

Read More →

TB laboratory manuals issued to support the implementation of WHO-recommended diagnostics

The World Health Organization and the Stop TB Partnership’s Global Laboratory Initiative working group release three new manuals to support the implementation of WHO-recommended TB diagnostics.

Read More →

Key changes to the treatment of drug-resistant TB

The World Health Organization issues rapid communication on updated guidance for the treatment of drug-resistant TB.

Read More →

WHO: Call for expressions of interest

The World Health Organization (WHO) is seeking expressions of interest from individuals or entities with relevant expertise to perform a systematic review of the evidence for the diagnostic accuracy of targeted next-generation sequencing technologies for detection of drug resistance among people diagnosed with TB.

Read More →

WHO launches a second report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services

27 April 2022 | Geneva: The World Health Organization (WHO) Global TB Programme is pleased to share its second report of country success stories in mitigating the impact of the COVID-19 pandemic on TB services.   

Read More →

Report of the WHO technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments

The World Health Organization (WHO) Global Tuberculosis Programme, in collaboration with University College London and other partners, convened a virtual technical consultation from 15 to 17 September 2021 that focused on innovative clinical trial designs that could be used for evaluating new tuberculosis (TB) preventive treatments (TPTs).

Read More →

WHO webinar: End TB E-learning platform

The World Health Organization (WHO) will host a webinar on 5 May 2022 to present the new WHO's End TB E-learning platform providing access to the new WHO e-courses on TB preventive treatment, TB diagnostics and drug-resistant TB. A question and answer session will also be offered.

Read More →

WHO announces updates on optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex

12 April 2022 | Geneva:  The broth microdilution plate method represents a promising solution for comprehensive and quality-assured phenotypic drug susceptibility testing in tuberculosis (TB). Using this method up to 12 anti-TB agents can be tested simultaneously providing quantitative levels of resistance and aid individualized patient treatment decisions. The document provides an optimized plate design and standardized methodology to facilitate the improvement of the method for clinical use. The World Health Organization (WHO) calls on manufacturers to take forward this optimized method and make it available for programmatic use in resource-limited settings.

Read More →

WHO announces updates on new TB antigen-based skin tests for the diagnosis of TB infection

04 April 2022 | Geneva:  Tuberculosis antigen-based skin tests (TBST), a new class of tests to diagnose TB infection, have been evaluated by the World Health Organization (WHO) and are found to be accurate, acceptable, feasible and cost-effective. These tests represent an alternative to tuberculin skin test (TST) and Interferon-Gamma Release Assays (IGRAs).

Read More →

Page 1 of 35 · Total posts: 10

1 2 Last→